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Purpose: To assess change in hospitalization and cost of care from 6 months pre- to 6 months 
post-initiation on any depot antipsychotic among schizophrenia patients.
Patients and methods: Using a large United States commercial claims and encounters 
database, patients younger than 65 years diagnosed with schizophrenia were identified. Patients 
initiated on a depot antipsychotic were studied in a mirror-image design to assess change in 
hospitalization rates, mean duration hospitalized, and hospitalization cost. McNemar’s test and 
paired t-tests compared the proportions of patients hospitalized and the mean duration. Paired 
t-test and bootstrapping methods compared costs.
Results: In these patients (n = 147), psychiatric hospitalizations declined from 49.7% 
pre-initiation to 22.4% post-initiation (P , 0.001), and the mean hospitalized duration for 
psychiatric purposes numerically declined from 7.3 to 4.7 days (P = 0.05). Total health care 
costs declined from $11,111 to $7884 (P , 0.05) driven by reduction in costs for psychiatric 
hospitalizations from $5384 to $2538 (P , 0.05).
Conclusion: Initiation of depot antipsychotic therapy appeared to be associated with a decline in 
hospitalization rates and costs. Current findings suggest that treatment with depot antipsychotics 
may be a cost-effective option for a subgroup of patients with schizophrenia who are at high 
risk of nonadherence with their oral antipsychotic medication regimen.
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Introduction
Longer treatment duration with antipsychotics is associated with better clinical and 
functional outcomes.1,2 Despite the benefits, many patients have difficulty sustaining 
maintenance treatment because of difficulties adhering to daily regimens of oral 
medications. More than 35% of patients have adherence issues during their first 4 to 
6 weeks of treatment3 and by 2 years, 75% are considered only partially adherent.4 
A 1998 study reported that patients receiving antipsychotics took an average of only 
58% of the recommended amount of the medications.5
Antipsychotics in long-acting injection form (“depot”) were developed in the 1960s 
to improve long-term schizophrenia treatment.6 Depot antipsychotics are often used 
to treat schizophrenia patients who are at high risk of nonadherence with their oral 
antipsychotics and, thus, also at a possible high risk of relapse and hospitalization.7,8 
Treatment with a depot antipsychotic requires the patient to visit the clinic every 1 to 
6 weeks to receive an intramuscular injection, which eliminates the patient’s need to 
take the oral antipsychotic medication daily.
Although the efficacy of oral antipsychotic medications has been compared with 
depot medications by using randomized clinical trials (RCTs), there are   difficulties ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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using RCTs in this patient group. For example, the patients 
who are most appropriate for depot treatment tend to 
have additional problems such as substance abuse and 
legal issues,9 making them less likely to enroll in RCTs. 
Patients who are switched to depot antipsychotics   generally 
have a history of poor adherence to oral antipsychotics 
and are   frequently coaxed into depot treatment via legal 
  commitments (“  compulsory treatment”) and thus unable 
to give a valid informed consent for a clinical trial. It has 
also been   suggested that RCTs are likely to recruit adherent 
patients selectively by excluding patients with   characteristics 
that are associated with poor adherence (eg, comorbid sub-
stance abuse).10 Yet these patients with poor adherence are 
the best candidates for depot treatment.
In contrast with RCTs, retrospective mirror-image studies 
do not require the patients to enroll in a study, as their medi-
cation and use of services in usual care are routinely captured 
in claims databases. Importantly, the mirror-image study 
design does not require a parallel active control group, as 
each patient serves as his or her own control. In these studies, 
patients maintained on oral medication are switched to depot 
medications and the outcome before and after the switch is 
compared. While some researchers reported a decline in 
the number of hospital admissions after initiation on depot 
antipsychotics,11,12 other researchers reported an increase in 
hospitalization days and resource utilization.13–15 Prior mirror-
image research publications have been confined to patients 
treated in the United Kingdom with one exception: one United 
States-based publication16 reported change in hospitalization 
and resource utilization after initiation of depot antipsychotics. 
In that study, from the Ohio Veterans Affairs (VA) Healthcare 
System, 75% of patients experienced a psychiatric-related 
hospitalization before depot initiation but only 42% were 
hospitalized during an equal amount of time after initiation. 
In addition to fewer psychiatric-related hospitalizations, these 
investigators reported shorter length of stay, fewer inpatient 
days per month, and one additional outpatient visit per month 
post-initiation. These researchers expressed a need for further 
United States studies in a non-VA population.
To fill this information gap and expand on the sparse United 
States-based research findings, the present mirror-  image study 
aimed to assess change in hospitalization risk from 6 months 
pre- to 6 months post-initiation on any depot antipsychotic 
among patients treated for schizophrenia in the United 
States. Hospitalization risk was defined as the proportion of 
patients hospitalized and the number of psychiatric hospital 
admissions. Secondary objectives included assessment of the 
change in patients’ adherence level, assessment of the change 
in utilization of outpatient services (emergency room, day 
treatment, and other outpatient visits), and assessment of the 
change in total direct cost and cost components (any inpatient 
hospitalization, psychiatric hospitalization, outpatient visits, 
and medication cost).
Material and methods
Data source
The data source for this study was the Thomson Medstat 
MarketScan commercial claims and encounters data-
bases (January 1, 2004 to March 31, 2008; MarketScan® 
Databases, Thomson Healthcare, Inc., Ann Arbor, MI). 
The databases capture person-specific clinical utilization, 
expenditures, and enrollment across inpatient, outpatient, 
prescription drug, and carve-out services from a selection of 
about 100 payers, including large employers, health plans, 
and government and public organizations. The MarketScan 
Databases link paid claims and encounter data over time 
and to detailed patient information across sites and types 
of providers, and over time.17
study sample selection
The sample selection consisted of patients (,65 years of 
age) who were diagnosed with schizophrenia (International 
Classification of Diseases [ICD]-9-CM codes 295.XX) 
between January 1, 2004 and March 31, 2008 and who had at 
least 2 outpatient visits or 1 inpatient   hospitalization   associated 
with the schizophrenia diagnosis. Patients   diagnosed with 
dementia type disorder were excluded. Patients who were 
initiated on any depot antipsychotic, who had no depot 
injection in the 6 months before this   injection, and who had 
continuous enrollment for the 6 months before and 6 months 
after the depot initiation date (“index date”) were included if 
the 2 outpatient visits or 1 inpatient   hospitalization occurred 
within 180 days before the depot initiation. The index date 
was the date of the first depot injection.
study measures
Patient demographics, including age and gender, were 
assessed for all patients. The specific antipsychotic depot 
medication, schizophrenia patients’ related medical comor-
bidities, and substance use were determined based on 
ICD-9-CM diagnosis codes during the 6-month pre-index 
period. During the 6-month pre-index period and 6-month 
post-index period, data were collected on the   proportion of 
patients hospitalized at least once for any reason,   hospitalized 
at least once with a psychiatric diagnosis, and hospitalized 
at least once with a schizophrenia diagnosis, the number ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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of   psychiatric hospital admissions, total number of days 
  hospitalized for psychiatric purposes, adherence with antip-
sychotic medication (defined as the Medication   Possession 
Ratio [MPR] – the proportion of days the patient is in 
  possession of any antipsychotic during each 180-day obser-
vation period), outpatient service use (emergency room, day 
treatment, and other office visits), total direct cost, and cost 
components (any hospitalization, psychiatric hospitaliza-
tions, outpatient services, and medication).
statistical methods
Patients’ baseline characteristics, comorbidities, and drug use 
disorders in the 6-month pre-index period were summarized. 
Analyses comparing the pre- vs post-initiation data employed 
McNemar’s test for categorical variables, including the 
proportion of patients hospitalized for psychiatric reasons 
and the proportion of patients who used outpatient services, 
and paired t-tests to assess the continuous variables including 
the mean number of admissions, mean of total hospitalized 
duration, and MPR. Mean cost comparisons were conducted 
with paired t-tests and bootstrapping methods. Because cost 
data frequently do not exemplify a typical random distribution 
(ie, they are usually right-skewed and truncated at zero due to 
a small number of patients with high costs, a large number of 
patients with no costs, and the impossibility of costs less than 
zero18), bootstrapping methods were used. Nonparametric 
bootstrapping is a technique where an empirical distribution 
of the mean cost difference between groups is constructed 
through resampling with replacement from the observed cost 
data. Bootstrapping is an alternative for analysis of cost data 
because it uses a nonparametric approach, which can directly 
address arithmetic means without making assumptions 
about the shape of the distribution.19 Bootstrap resampling 
(5000 iterations) was used to provide a nonparametric 
comparison of total cost as well as component costs 
(eg, any hospitalization cost, psychiatric hospitalization cost, 
outpatient cost, and medication cost) in the 6-month pre- vs 
post-index periods. No statistical adjustments were made 
for the multiple comparisons. Sensitivity analyses include 
examining the impact of acute care costs occurring just after 
the medication change, which may be incurred due to the 
failure on the prior treatment.20
Results
From a total of 674 patients with schizophrenia who were 
initiated on depot antipsychotics, data from 147 patients 
met inclusion criteria and were included in the analyses 
(Figure 1). Their baseline characteristics are presented in 
Table 1, showing that the mean age was the early 40s and 
slightly more than half of patients were male.
After initiation of depot antipsychotics, patients improved 
their medication adherence. Mean antipsychotic MPR increased 
from 36.8% in the 6 months preceding depot initiation to 
60.0% in the 6 months after initiation (P , 0.001). After 
depot   initiation, patients were less likely to be hospitalized for 
any reason, for any psychiatric reason, and for   schizophrenia 
  specifically (Table 2). During the 6 months preceding initia-
tion, 79 patients (53.7%) were hospitalized for any   reason com-
pared with 44 patients (29.9%) in the 6 months after   initiation 
(P , 0.001). Hospitalization for any   psychiatric   reason 
decreased from 73 patients (49.7%) to 33 patients (22.4%; 
P , 0.001). Hospitalization for schizophrenia decreased from 
63 patients (42.9%) to 30 patients (20.4%; P , 0.001).
Depot initiators
N = 674
Patients without 
dementia diagnosis
n = 662
Patients with 
dementia diagnosis
n = 12
Patients with 180 days 
before and after eligibility
n = 262
Patients without 180 days
before and after eligibility
n = 400
Patients with 2 outpatient
visits or 1 inpatient
admission with a 
schizophrenia diagnosis in
the prior 180 days 
n = 147
Patients without 2 
outpatient visits or 1 
inpatient admission with a
schizophrenia diagnosis in
the prior 180 days
n = 115
Figure 1 Patient flowchart.
Table 1 Patient baseline characteristics
no. of patients who initiated depot, n 147
Specific depot medication, n (%)
  Risperidone long-acting 38 (25.9)
  haloperidol decanoate 69 (46.9)
  Fluphenazine decanoate 40 (27.2)
Age at initiation, mean (SD) 42.6 (14.7)
Male, n (%) 79 (53.7)
Medical comorbidities, n (%)
  Congestive heart failure 3 (2.0)
  Chronic pulmonary disease 13 (8.8)
  Mild liver disease 4 (2.7)
  Diabetes 20 (13.6)
  Diabetes with chronic complications 1 (0.7)
Substance use disorder, n (%) 17 (11.6)
  Alcohol use, n (%) 4 (2.7)
  Drug use, n (%) 14 (9.5)
Abbreviation: sD, standard deviation.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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The mean number of hospitalizations for any reason 
decreased from 0.78 to 0.41 (P , 0.001). The mean number 
of inpatient psychiatric admissions decreased from 0.67 to 
0.31 (P , 0.001). The mean number of hospitalizations for 
schizophrenia decreased from 0.53 to 0.29 (P = 0.002). There 
were nonsignificant trends for decreases in the mean number 
of days of hospitalization for any reason (from 8.0 to 5.3; 
P = 0.067) and for psychiatric hospitalization (from 7.3 to 
4.7; P = 0.054). The mean number of days of hospitalization 
for schizophrenia decreased from 5.7 to 4.0 but this change 
was not significant (P = 0.190).
During the 6 months preceding initiation, 36.1% of 
patients had 1 hospitalization for any reason, 12.2% had 2, 
and 5.5% had 3 or more. In the 6 months after initiation, 
21.8% had 1 hospitalization for any reason, 5.4% had 2, and 
2.7% had 3 or more. During the 6 months preceding initiation, 
35.4% of patients had 1 hospitalization for psychiatric reasons, 
12.2% had 2, and 2.1% had 3 or more. In the 6 months after 
initiation, 16.3% had 1 hospitalization for psychiatric reasons, 
4.1% had 2, and 2.0% had 3 or more. During the 6 months 
preceding initiation, 34.0% of patients had 1 hospitalization 
for schizophrenia, 7.5% had 2, and 1.4% had 3 or more. In 
the 6 months after initiation, 14.3% had 1 hospitalization for 
schizophrenia, 4.1% had 2, and 2.0% had 3 or more.
Change in outpatient service use was not significant. 
From the 6 months before depot initiation to the 6 months 
after initiation, the percent of patients who used emergency 
room services changed from 25.2% to 19.1%, the percentage 
of patients who used day treatment changed from 56.5% to 
53.7%, and the percentage of patients having office visits 
changed from 88.4% to 86.4%.
Mean total direct costs of treatment decreased from 
$11,111.30 in the 6 months before depot initiation to 
$7883.80 in the 6 months after initiation (P , 0.05; 
Table 3). Median total direct costs decreased from $7089.40 
to $4051.93. Mean total inpatient costs decreased from 
$6696.40 to $3593.20 (P , 0.05) and psychiatric-related 
inpatient costs decreased from $5384.20 to $2537.70 
(P , 0.05). Total outpatient costs and total medication costs 
did not change significantly. Median total outpatient costs 
decreased from $1591.05 to $1297.62. Median total medica-
tion costs were slightly changed ($853.04 before depot initia-
tion and $851.46 after initiation). The sensitivity analyses 
indicated that mean total direct costs of treatment decreased 
from $10,615.60 in the 6 months before depot initiation to 
$8379.50 in the 6 months after initiation (P , 0.05).
Discussion
This study used a mirror-image design to assess and compare 
hospitalization risk and health care costs during the 6 months 
before and 6 months after initiation of depot antipsychotics 
for the treatment of patients with schizophrenia in the United 
States. This study found an improvement in medication 
adherence, a decrease in the rate of psychiatric hospitalization 
for any reason, for any psychiatric reason, and for schizophrenia 
specifically, and a decrease in health care costs after patients 
initiated depot antipsychotics. These results suggest that 
Table 2 Change in hospitalization parameters in the 6 months 
pre- vs 6 months post-depot initiation
Before  
initiation
After  
initiation
P-valuea
Proportion of patients  
hospitalized at least 
once for any reason, n (%) 
79 (53.7) 44 (29.9) ,0.001
Proportion of patients  
hospitalized at least once for  
psychiatric reasons, n (%) 
73 (49.7) 33 (22.4) ,0.001
Proportion of patients  
hospitalized at least once  
for schizophrenia, n (%) 
63 (42.9) 30 (20.4) ,0.001
inpatient psychiatric  
admissions, mean (SD)
0.67 (0.80) 0.31 (0.65) ,0.001
Days hospitalized for any  
reason, mean (SD)
8.0 (12.2) 5.3 (13.2) 0.067
Days hospitalized for  
psychiatric reasons, mean (SD)
7.27 (11.6) 4.73 (13.1) 0.054
Days hospitalized for  
schizophrenia, mean (SD)
5.7 (9.2) 4.0 (11.7) 0.190
Note:  aPaired t-test for continuous variable and Mcnemar’s test for categorical 
variable.
Abbreviation: sD, standard deviation.
Table 3 Change in total cost (US$) and cost component in the 6 months pre- vs 6 months post-depot initiation
Mean (SD) Six months pre-depot initiation Six months post-depot initiation P-value
Total cost $11,111.30 ($12,551.70) $7883.80 ($9481.30) 0.003
Total inpatient cost $6696.40 ($10,620.40) $3593.20 ($7806.20) 0.002
Psychiatric inpatient cost $5384.20 ($8703.40) $2537.70 ($6678.70) ,0.001
schizophrenia inpatient cost $4143.30 ($7568.00) $2377.30 ($6561.50) 0.017
Total outpatient cost $2862.16 ($3681.64) $2557.77 ($2919.90) 0.300
Total medication cost $1552.82 ($2047.31) $1732.78 ($2713.65) 0.220
Abbreviation: sD, standard deviation.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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depot antipsychotic therapy may be a cost-effective option 
for a subgroup of patients typically at high risk of nonadher-
ence with their oral antipsychotic regimen.9
Current findings are consistent with prior research in and 
outside the United States. A study in a VA population in the 
United States by Fuller et al16 found decreases in psychiatric-
related hospitalization from 75% to 42% after initiation of 
depot antipsychotics. In addition to fewer psychiatric-related 
hospitalizations, these researchers reported shorter length of 
stay, fewer inpatient days/month, and one additional outpa-
tient visit/month post-initiation. Our results are also consis-
tent with two United Kingdom studies that reported a decline 
in the proportion of patients requiring hospital admissions 
after initiation of depot antipsychotics.11,12 The Taylor et al11 
study reported a decline in hospital admission rate from 62% 
before to 22% after initiation of depot. Similarly, the study by 
Niaz and Haddad12 found a reduction in hospital admissions, 
compulsory admissions, and total inpatient days.
Our study expanded on prior research by demonstrating 
an increase in medication adherence after initiating depot 
antipsychotics. This is important because patients being 
treated for schizophrenia often have problems with adherence 
to medications, and stopping medication often has serious 
consequences.21 Increased adherence with depot antipsychotics 
has the additional benefit of allowing clinicians to differentiate 
compliance failure from efficacy failure which can reduce the 
use of rescue medications and the need for switching to a second-
choice antipsychotic.22 Our study also demonstrated potential 
cost savings following depot initiation. Cost analyses found a 
significant decline in total cost of treatment, driven by decline 
in hospitalization cost from pre- to-post-depot initiation.
Results need to be considered in the context of the study 
limitations. The sample size was rather small (n = 147). Also, 
the study design is devoid of a control group. In this mirror-
image study, each patient served as his or her own control. 
As such, observed changes from pre- to post-depot initiation 
may reflect regression to the mean. Thus, we cannot determine 
if similar or even better results would have occurred with a 
different intervention. In addition, we used data from a large 
United States commercial claims and encounters database. 
Findings may not be generalizable to patients with schizophre-
nia who lack commercial insurance, which is a large segment 
of the schizophrenia population in the United States.
Conclusion
In summary, results from this study suggest that initiating 
depot antipsychotic therapy is associated with declines in 
hospitalization rates and related costs, compared with the 
prior treatment periods. These findings also suggest that 
treatment with depot antipsychotics may be a cost-effective 
option for a subgroup of patients with schizophrenia who 
are at high risk of nonadherence with their oral antipsychotic 
medication regimen.
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